|
CURRICULUM VITAE
|
| SCOTT S. FERER, M.D. |
|
|
Board Certification
|
American Board of Psychiatry and Neurology, Certificate #44542, December 1997
|
|
Licensure
|
California Medical Board G075954 Drug Enforcement Administration BF5221217 National Board of Medical Examiners #397760
|
|
Employment
|
Private Practice Orange County Memory Assessment Center Newport Beach, California March 1999 - present
Clinical Research Sub-Investigator,
Medical Consultant, Unum Life
Mullikin Medical Center, Artesia, CA
First Physicians Medical Group
|
|
Post graduate Training
|
|
|
Fellowships
|
EMG/Neuromuscular Disease Department of Neurology Louisiana State University Medical Center Austin J. Sumner, Fellowship Director and Chairman July 1996 to June 1997
Neurodiagnostics (EMG, EEG, EP)
|
|
Residency
|
Department of Neurology University of California, Irvine Medical Center Stanley van den Noort, Chairman Robert R. Young, Residency Director July 1992 to June 1995 Chief Resident, 1994 to 1995
Superior Performance Award
|
|
Internship
|
Department of Medicine University of California, Irvine Medical Center June 1991 to June 1992
|
|
Education
|
|
|
Doctor of Medicine
|
University of Kansas School of Medicine Kansas City, KS 1991
|
|
Bachelor of Science
|
University of California, Santa Barbara Biopsychology with honors, 1987
|
|
Memberships
|
American Academy of Neurology American Medical Association Orange County Neurological Association
|
|
Research
|
Amparo Gutierrez MD, John D. England MD, Austin J. Sumner MD, Scott Ferer MD, Laura E. Warner PhD,
James R. Lupski MD PhD, and Carlos A. Garcia MD. Unusual Electrophysiologic Findings in a family with CMT - X. Muscle & Nerve 23: 182-188, 2000
|
|
Dec 2003 to Feb 2004:
|
GlaxoSmithKline: Protocol# SUM30047: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumitriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine.
|
|
Dec 2003 to Sept 2004:
|
GlaxoSmithKline: Protocol# NPP30010: A Multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of lamotrigine in subjects with neuropathic pain and inadequate pain relief with gabapentin, tricyclic antidepressants or non-narcotic analgesics.
|
|
Dec 2003 to May 2004:
|
Merck & Co., Inc.: Protocol# MTEP (Migraine Therapy Evaluation Protocol): A Multicenter, Open-Label, Crossover Study Comparing Maxalt� (Rizatripatan Benzoate) With Usual Care Oral Migraine Medications
|
|
Feb 2004 to June 2004:
|
Bertek Pharmaceuticals, Inc. (clinical study managed by PPD-CRO), Protocol# "IMPACT (Implications of Motor Fluctuations in Parkinson's Patients on Chronic Therapy) Registry.
|
|
Apr 2004 to Nov 2005:
|
GlaxoSmithKline: Protocol#101468/228: Parkinson's Disease Onset of Motor Complications
|
|
July 2004 to Jan 2005:
|
Ortho-McNeil: Protocol#CAPSS-342: 329-02-04 AXERT® 12.5mg
Time vs Intensity-Migraine Study (AIMS) An Open-Label
Multicenter Trial to Evaluate the Efficacy of AXERT 12.5mg
Intervention at Onset of Migraine Pain.
|
|
July 2004 to 2005:
|
Protocol# PIND#101: Pain Control and Improved Functioning in Patients with Chronic Pain with AVINZA.
|
|
Sep 2004 to Mar 2005:
|
Pozen Inc.: Protocol# MT400-302: A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy Of Trexima™ in Acute Treatment of Migraine Headaches.
|
|
Oct 2004 to Present:
|
GlaxoSmithKline: Protocol# LAM100034: A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Subjects with Partial Seizures.
|
|
Oct 2004 to Present:
|
GlaxoSmithKline: Protocol# LAM100036: A Muticenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures.
|
|
May 2005 to Feb 2006:
|
Merck & Co: Protocol# 072/MAX565: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Rizatriptan 10-mg Tablet for the Treatment of Menstrual Migraine.
|
|
Oct 2005 to Feb 2007:
|
TEVA Neuroscience (clinical study managed by Pharmanet): Protocol# TNC GA MS 2004_01: A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the Add-On Effect of Oral Steroids in Relapsing Remitting Multi Sclerosis Subjects Treated with Glatiramer Acetate (GA).
|
|
Oct 2005 - June 2006:
|
GlaxoSmithKline: Protocol# TRX103632: A Randomized, Double-Blind, Multi Center,Placebo-Controlled, Cross-Over Study to Determine the Consistency
Of Response for Trexima™(Sumatriptan 85mg/Naproxen Sodium 500mg) Administered
During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks.
|
|
Nov 2005 to Nov 2006:
|
Merck & Co: Protocol#074-00: A Randomized, Doble-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Patients Treated with Rizatriptan Orally Disintegrating Tablet(ODT).
|
|
Nov 2005 to May 2006:
|
POZEN Inc.:Protocol#LNP201: A Randomized, Double-Blind, Single Dose, Placebo-Controlled Evaluation of the Safety and Efficacy of Intravenous Lornoxicam in the AcuteTreatment of the Headache of Migraine.
|
|
Jan 2006 to Present:
|
Protocol#191622-080: A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase.
|
|
Apr 2006 to Oct 2006:
|
Protocol#TRX105850: A randomized, double-blind, single migraine attack, placebo-controlled, parallel-group multicenter study to evaluate the efficacy and tolerability of Trexima™ (sumatriptan succinate/ naproxen sodium) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea.
|
|
Mar 2006 to Jan 2007:
|
Protocol# SK&F-101468/204: A 12-Week, Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared with Ropirinole Immediate Release (IR) Tablets in Subjects with Restless Leg Syndrome (RLS).
|
|
Aug 2006 to Present:
|
Protocol# TXA107563: A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TreximaTM (sumatriptan succinate/naproxen sodium) for a single moderate or severe headache in adults diagnosed with probable migraine without aura (ICHD-II 1.6.1).
|
|
Oct 2006 to Present:
|
Protocol#TRX106571: A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Eletriptan (Study 1 of 2).
|
|
Feb 2007 to Present:
|
Protocol# AVA105640: A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1).
|
|
Research Site Address:
|
Newport Beach Clinical Research Associates, Inc. 400 Newport Center Drive., Suite# 701 Newport Beach, CA 92660 Tel: 949.759.8001/Fax: 949.760.3671
|
|
Activities and Interests
|
Golf Weight Training/Physical Fitness All spectator sports Travel
|
|
References
|
Available Upon Request
|